RESUMEN
OBJECTIVE: To manage three cases of mild to moderate fluorosis by resin infiltration technique and to quantify the tooth color changes by measuring CIE L*a*b* values of digital photographs and calculating ΔE00 based on the CIEDE2000 formula using Adobe Photoshop software. METHODS AND MATERIALS: Three cases of mild to moderate fluorosis were treated with a combination of bleaching and a resin infiltration technique. CIE L*a*b* values of 18 fluorosed spots were measured from digital photographs of these cases at four different stages-preoperative, postbleaching, postinfiltration and at 12-month follow-up-using Adobe Photoshop software, and ΔE00 was calculated based on the CIEDE2000 formula. The ΔE00 values of all 18 points obtained at different stages were submitted to statistical analysis (α=0.05). RESULTS: In all the cases reported, clinically as well as by the photographic color analysis, it was found that the technique masked the lesions, improving the patients' esthetics, which was maintained even at 12-month recall. Statistically significant difference in ΔE00 values was present between comparison of all stages (p<0.001) except between postinfiltration and the 12-month follow-up stage (p=0.642). CONCLUSION: A resin infiltration technique helped in the satisfactory management of white spot lesions of fluorosis, which were stable even at 12-month follow up. Quantitation of the changes was achieved using Adobe Photoshop software.
Asunto(s)
Fluorosis Dental , Color , Estudios de Seguimiento , Humanos , FotograbarRESUMEN
STUDY OBJECTIVE: To investigate the effects of priming rocuronium on the time course of neuromuscular blockade. DESIGN: Prospective, controlled, randomized clinical study. SETTING: University teaching hospital. PATIENTS: 42 ASA physical status I and II patients undergoing peripheral surgery with general anesthesia. INTERVENTIONS: Following a standardized propofol-fentanyl induction, patients in Group 1 (n = 21) received a priming dose of rocuronium 0.06 mg/kg followed two minutes later by an intubating dose of rocuronium 0.54 mg/kg. Patients in Group 2 (n = 21) received a saline placebo injection followed two minutes later by rocuronium 0.6 mg/kg. Anesthesia was maintained with isoflurane and nitrous oxide 60% in oxygen. MEASUREMENTS AND MAIN RESULTS: Neuromuscular function was assessed at the wrist using mechanomyography with a single-twitch mode of stimulation at a frequency of 1 Hz until tracheal intubation and at 0.1 Hz thereafter. The times from injection of the intubating dose of rocuronium until 95% suppression of the twitch tension (onset time), recovery of twitch tension to 25% of control (clinical duration of action), and the time from 25% to 75% spontaneous recovery of twitch tension (recovery index) were recorded. The trachea was intubated at 95% depression of the twitch tension and the intubating conditions were graded using a 3-point scale. The onset times with priming rocuronium (34 +/- 6 s) were significantly shorter (p < 0.01) than those without priming (59 +/- 14 s). The intubation conditions were similar in the two groups; however, the intubating times with priming were significantly shorter. The clinical duration of action and the recovery index did not differ significantly between the two groups. CONCLUSIONS: Priming rocuronium decreased the onset times and thus, the intubating times without increasing the clinical duration of action or recovery index.
Asunto(s)
Androstanoles , Anestesia por Inhalación , Bloqueo Nervioso , Fármacos Neuromusculares no Despolarizantes , Adulto , Androstanoles/administración & dosificación , Método Doble Ciego , Femenino , Humanos , Intubación Intratraqueal , Masculino , Monitoreo Intraoperatorio , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Premedicación , RocuronioRESUMEN
UNLABELLED: The effects of neostigmine on the incidence of postoperative nausea and vomiting (PONV) are controversial. In this study, we evaluated the effects of neostigmine and glycopyrrolate on the incidence of PONV and the need for antiemetics in patients undergoing ambulatory surgery. One hundred healthy patients undergoing outpatient surgical procedures were included in the study. A standardized anesthetic technique was used for all patients. Patients were randomized to receive either mivacurium (n = 50) or rocuronium (n = 50) to achieve muscle paralysis. Bolus doses of mivacurium 2-4 mg or rocuronium 5-10 mg were administered to maintain one or two twitches of the train-of-four stimulation of the ulnar nerve at the wrist. After surgery, residual neuromuscular blockade was reversed with neostigmine 2.5 mg i.v. and glycopyrrolate 0.5 mg i.v. only if clinically deemed necessary (i.e., fade on train-of-four stimulation, inadequate tidal volume, reduced hand grip, or inability to maintain head lift). The incidence of PONV and the need for antiemetics were recorded in the post-anesthesia care unit (PACU), in the phase II unit, and 24 h after surgery. We compared patients who received neostigmine (n = 40) for reversal of residual neuromuscular blockade with those who did not (n = 60). More patients receiving rocuronium required reversal drugs than those receiving mivacurium (68% vs 10%). There were no differences in the incidence of nausea (18% vs 15%), vomiting (8% vs 12%), and the need for antiemetics (13% in both the groups) in the PACU between patients who received neostigmine and those who did not. In addition, the duration of PACU stay and the time to home-readiness were also similar between the groups. We conclude that, compared with rocuronium, the use of mivacurium decreases the need for reversal drugs. In addition, reversal of residual neuromuscular blockade with neostigmine does not increase the incidence of PONV or the need for antiemetic medications in patients undergoing ambulatory surgery. IMPLICATIONS: In this study, we showed that the incidence of postoperative nausea and vomiting and the need for antiemetics do not increase with the use of neostigmine and glycopyrrolate for reversal of residual muscle paralysis.